The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the ...
Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made ...
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
The push to develop the first oral GLP-1 receptor drug for obesity is heating up, as four phase 3 drugs race to become the first approved oral treatment for obesity, Global Data reported Dec. 2.
U.S. Food and Drug Administration Commissioner Robert Califf defended the agency's role in addressing the country's obesity ...
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
Oh dear, Keir. In late October, I issued a 100-day appeal for the gloomsters and doomsters to pipe down and just let the new ...
Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...